Terms: = Germ cell tumor AND PMS2, HNPCC4, 5395, ENSG00000122512, H_DJ0042M02_9, PMSL2, PMS2CL
5769 results:
1. A qualitative evaluation of factors influencing tumor Treating fields (TTFields) therapy decision making among brain tumor patients and physicians.
Kumthekar P; Lyleroehr M; Lacson L; Lukas RV; Dixit K; Stupp R; Kruser T; Raizer J; Hou A; Sachdev S; Schwartz M; Pa JB; Lezon R; Schmidt K; Amidei C; Kaiser K
BMC Cancer; 2024 Apr; 24(1):527. PubMed ID: 38664630
[TBL] [Abstract] [Full Text] [Related]
2. Demographic bias in misdiagnosis by computational pathology models.
Vaidya A; Chen RJ; Williamson DFK; Song AH; Jaume G; Yang Y; Hartvigsen T; Dyer EC; Lu MY; Lipkova J; Shaban M; Chen TY; Mahmood F
Nat Med; 2024 Apr; 30(4):1174-1190. PubMed ID: 38641744
[TBL] [Abstract] [Full Text] [Related]
3. Travel burdens to access care among children with cancer between 2016 and 2019: Analysis of a national population-based cancer registry in Japan.
Tsutsui A; Murakami Y; Okamura S; Fujimaki T; Endo M; Ohno Y
PLoS One; 2024; 19(4):e0300840. PubMed ID: 38625911
[TBL] [Abstract] [Full Text] [Related]
4. In Silico Transcriptomic Expression of MSR1 in Solid tumors Is Associated with Responses to Anti-PD1 and Anti-CTLA4 Therapies.
Sanvicente A; Díaz-Tejeiro C; Nieto-Jiménez C; Paniagua-Herranz L; López Cade I; Balázs G; Moreno V; Pérez-Segura P; Calvo E; Ocaña A
Int J Mol Sci; 2024 Apr; 25(7):. PubMed ID: 38612803
[TBL] [Abstract] [Full Text] [Related]
5. Exploring Regorafenib Responsiveness and Uncovering Molecular Mechanisms in Recurrent Glioblastoma tumors through Longitudinal In Vitro Sampling.
Morelli M; Lessi F; Franceschi S; Ferri G; Giacomarra M; Menicagli M; Gambacciani C; Pieri F; Pasqualetti F; Montemurro N; Aretini P; Santonocito OS; Di Stefano AL; Mazzanti CM
Cells; 2024 Mar; 13(6):. PubMed ID: 38534332
[TBL] [Abstract] [Full Text] [Related]
6. De novo missense variants in exon 9 of SEPHS1 cause a neurodevelopmental condition with developmental delay, poor growth, hypotonia, and dysmorphic features.
Mullegama SV; Kiernan KA; Torti E; Pavlovsky E; Tilton N; Sekula A; Gao H; Alaimo JT; Engleman K; Rush ET; Blocker K; Dipple KM; Fettig VM; Hare H; Glass I; Grange DK; Griffin M; Phornphutkul C; Massingham L; Mehta L; Miller DE; Thies J; Merritt JL; Muller E; Osmond M; Sawyer SL; Slaugh R; Hickey RE; Wolf B; ; ; Choudhary S; Simonović M; Zhang Y; Palculict TB; Telegrafi A; Carere DA; Wentzensen IM; Morrow MM; Monaghan KG; Yang J; Juusola J
Am J Hum Genet; 2024 Apr; 111(4):778-790. PubMed ID: 38531365
[TBL] [Abstract] [Full Text] [Related]
7. NPS-2143 inhibit glioma progression by suppressing autophagy through mediating AKT-mTOR pathway.
Nie JL; Li Q; Yin HT; Yang JH; Li M; Li Q; Fan XH; Zhao QQ; Wen ZP
J Cell Mol Med; 2024 Apr; 28(7):e18221. PubMed ID: 38509759
[TBL] [Abstract] [Full Text] [Related]
8. Recurrence Patterns and Surveillance Imaging in Pediatric Brain tumor Survivors.
Cacciotti C; Lenzen A; Self C; Pillay-Smiley N
J Pediatr Hematol Oncol; 2024 Apr; 46(3):e227-e232. PubMed ID: 38447113
[TBL] [Abstract] [Full Text] [Related]
9. The Impact of Posttreatment Imaging in Peptide Receptor Radionuclide Therapy.
Yadav S; Lawhn-Heath C; Paciorek A; Lindsay S; Mirro R; Bergsland EK; Hope TA
J Nucl Med; 2024 Mar; 65(3):409-415. PubMed ID: 38428966
[TBL] [Abstract] [Full Text] [Related]
10. Radiolabeled Somatostatin Receptor Antagonist Versus Agonist for Peptide Receptor Radionuclide Therapy in Patients with Therapy-Resistant Meningioma: PROMENADE Phase 0 Study.
Eigler C; McDougall L; Bauman A; Bernhardt P; Hentschel M; Blackham KA; Nicolas G; Fani M; Wild D; Cordier D
J Nucl Med; 2024 Apr; 65(4):573-579. PubMed ID: 38423782
[TBL] [Abstract] [Full Text] [Related]
11. Assessment of Social Vulnerabilities of Care and Prognosis in Adult Ocular Melanomas in the US.
Mensah JA; Fei-Zhang DJ; Rossen JL; Rahmani B; Bentrem DJ; Stein JD; French DD
Ann Surg Oncol; 2024 May; 31(5):3302-3313. PubMed ID: 38418655
[TBL] [Abstract] [Full Text] [Related]
12. Hand2 Immunohistochemistry in the Diagnosis of Paragangliomas and Other Neuroendocrine Neoplasms.
Soukup J; Manethova M; Stejskal V; Novakova M; Duskova J; Hornychova H; Hacova M; Staniczkova-Zambo I; Zelinka T; Kosak M; Cesak T; Netuka D; Ryska A; Gabalec F
Endocr Pathol; 2024 Mar; 35(1):14-24. PubMed ID: 38416360
[TBL] [Abstract] [Full Text] [Related]
13. Immunogenicity of avelumab in patients with metastatic Merkel cell carcinoma or advanced urothelial carcinoma.
Hu P; Dai HI; Bourdage J; Zhou D; Trang K; Kowalski K; Bello C; Hibma J; Khandelwal A; Cowan K; Dong J; Venkatakrishnan K; Gao W
Clin Transl Sci; 2024 Mar; 17(3):e13730. PubMed ID: 38411318
[TBL] [Abstract] [Full Text] [Related]
14. tumor Treating Fields (TTFields) combined with the drug repurposing approach CUSP9v3 induce metabolic reprogramming and synergistic anti-glioblastoma activity in vitro.
Cao Q; Hajosch A; Kast RE; Loehmann C; Hlavac M; Fischer-Posovszky P; Strobel H; Westhoff MA; Siegelin MD; Wirtz CR; Halatsch ME; Karpel-Massler G
Br J Cancer; 2024 May; 130(8):1365-1376. PubMed ID: 38396172
[TBL] [Abstract] [Full Text] [Related]
15. Adjuvant dendritic cell therapy in stage IIIB/C melanoma: the MIND-DC randomized phase III trial.
Bol KF; Schreibelt G; Bloemendal M; van Willigen WW; Hins-de Bree S; de Goede AL; de Boer AJ; Bos KJH; Duiveman-de Boer T; Olde Nordkamp MAM; van Oorschot TGM; Popelier CJ; Pots JM; Scharenborg NM; van de Rakt MWMM; de Ruiter V; van Meeteren WS; van Rossum MM; Croockewit SJ; Koeneman BJ; Creemers JHA; Wortel IMN; Angerer C; Brüning M; Petry K; Dzionek A; van der Veldt AA; van Grünhagen DJ; Werner JEM; Bonenkamp JJ; Haanen JBAG; Boers-Sonderen MJ; Koornstra RHT; Boomsma MF; Aarntzen EHJ; Gotthardt M; Nagarajah J; de Witte TJM; Figdor CG; de Wilt JHW; Textor J; de Groot JWB; Gerritsen WR; de Vries IJM
Nat Commun; 2024 Feb; 15(1):1632. PubMed ID: 38395969
[TBL] [Abstract] [Full Text] [Related]
16. Combined visual and quantitative assessment of somatostatin receptor scintigraphy for staging and restaging of neuroendocrine tumors.
Ueki Y; Otsuka H; Otani T; Kasai R; Otomi Y; Ikemitsu D; Azane S; Kunikane Y; Bando T; Matsuda N; Okada Y; Takayama T; Harada M
Jpn J Radiol; 2024 May; 42(5):519-535. PubMed ID: 38345724
[TBL] [Abstract] [Full Text] [Related]
17. ARID2 mutations may relay a distinct subset of cutaneous melanoma patients with different outcomes.
Akinjiyan FA; Nassief G; Phillipps J; Adeyelu T; Elliott A; Abdulla F; Zhou AY; Souroullas G; Kim KB; Vanderwalde A; Park SJ; Ansstas G
Sci Rep; 2024 Feb; 14(1):3444. PubMed ID: 38341515
[TBL] [Abstract] [Full Text] [Related]
18. Hydrophilic molecularly imprinted resin-hexagonal boron nitride composite as a new adsorbent for selective extraction and determination of a carcinoid tumor biomarker in urine.
Cao J; Wang M; Han Y; Wang M; Yan H
Anal Chim Acta; 2024 Mar; 1294():342289. PubMed ID: 38336412
[TBL] [Abstract] [Full Text] [Related]
19. Divergent HLA variations and heterogeneous expression but recurrent HLA loss-of- heterozygosity and common
Lim WC; Marques Da Costa ME; Godefroy K; Jacquet E; Gragert L; Rondof W; Marchais A; Nhiri N; Dalfovo D; Viard M; Labaied N; Khan AM; Dessen P; Romanel A; Pasqualini C; Schleiermacher G; Carrington M; Zitvogel L; Scoazec JY; Geoerger B; Salmon J
Front Immunol; 2023; 14():1265469. PubMed ID: 38318504
[TBL] [Abstract] [Full Text] [Related]
20. Pan-cancer analyses of bromodomain containing 9 as a novel therapeutic target reveals its diagnostic, prognostic potential and biological mechanism in human tumours.
Chen Y; Gao Z; Mohd-Ibrahim I; Yang H; Wu L; Fu Y; Deng Y
Clin Transl Med; 2024 Feb; 14(2):e1543. PubMed ID: 38303608
[TBL] [Abstract] [Full Text] [Related]
[Next]
